Literature DB >> 31788125

miR-125b suppresses cellular proliferation by targeting c-FLIP in gallbladder carcinoma.

Huajie Zong1, Huading Zhou1, Yang Xiang1, Gang Wu1.   

Abstract

Gallbladder carcinoma (GBC) is the most common malignant tumor of the biliary tract. The incidence rate of gallbladder cancer ranks sixth among gastrointestinal types of cancer, and its incidence is increasing each year. Further clarification of the pathogenesis of GBC is essential, and identification of novel effective treatments is required. It has been previously demonstrated that high expression of the anti-apoptotic protein cellular Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein (c-FLIP) in GBC inhibited apoptosis in gallbladder cancer cells. In subsequent experiments, it was observed that microRNA (miR)-125b could target c-FLIP and inhibit the protein expression of c-FLIP by binding to the 3'untranslated regions of c-FLIP mRNA. In addition, the expression of miR-125b in GBC was significantly decreased, and the growth of gallbladder cancer cells was inhibited by the overexpression of miR-125b. The present study demonstrated that miR-125b could suppress the proliferation of gallbladder cancer cells by targeting c-FLIP. c-FLIP enriched the target gene pathway of miR-125b and may serve as a novel target for the treatment of GBC.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  c-FLIP; cell growth; gallbladder carcinoma; microRNA-125b

Year:  2019        PMID: 31788125      PMCID: PMC6865830          DOI: 10.3892/ol.2019.11000

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

Review 1.  Targeting c-FLIP in cancer.

Authors:  Sarah Shirley; Olivier Micheau
Journal:  Cancer Lett       Date:  2010-11-10       Impact factor: 8.679

2.  Prediction of prognosis in gallbladder carcinoma by mucin and p53 immunohistochemistry.

Authors:  Mayuko Takagawa; Naoki Muguruma; Kaori Oguri; Yoshitaka Imoto; Koichi Okamoto; Kunio Ii; Susumu Ito
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

3.  Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

Authors:  Clare McCourt; Pamela Maxwell; Roberta Mazzucchelli; Rodolfo Montironi; Marina Scarpelli; Manuel Salto-Tellez; Joe M O'Sullivan; Daniel B Longley; David J J Waugh
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

4.  Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Authors:  Yong Sang Hong; Jeeyun Lee; Sang Cheol Lee; In Gyu Hwang; Seong-Ho Choi; Jin-Seok Heo; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang
Journal:  Cancer Chemother Pharmacol       Date:  2006-12-02       Impact factor: 3.333

5.  MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20).

Authors:  Sang-Woo Kim; Kumaraguruparan Ramasamy; Hakim Bouamar; An-Ping Lin; Daifeng Jiang; Ricardo C T Aguiar
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-01       Impact factor: 11.205

6.  MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation.

Authors:  Lei Shi; Junxia Zhang; Tianhong Pan; Jinfang Zhou; Weiyi Gong; Ning Liu; Zhen Fu; Yongping You
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

7.  Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.

Authors:  Jeffrey A Meyerhardt; Andrew X Zhu; Keith Stuart; David P Ryan; Lawrence Blaszkowsky; Nicole Lehman; Craig C Earle; Matthew H Kulke; Pankaj Bhargava; Charles S Fuchs
Journal:  Dig Dis Sci       Date:  2007-06-29       Impact factor: 3.199

Review 8.  Targeting the extrinsic apoptosis pathway in cancer.

Authors:  Avi Ashkenazi
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-20       Impact factor: 7.638

9.  c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications.

Authors:  P Korkolopoulou; A A Saetta; G Levidou; F Gigelou; A Lazaris; I Thymara; M Scliri; K Bousboukea; N V Michalopoulos; N Apostolikas; A Konstantinidou; M Tzivras; E Patsouris
Journal:  Histopathology       Date:  2007-06-08       Impact factor: 5.087

10.  Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.

Authors:  P Geserick; C Drewniok; M Hupe; T L Haas; P Diessenbacher; M R Sprick; M P Schön; F Henkler; H Gollnick; H Walczak; M Leverkus
Journal:  Oncogene       Date:  2007-12-17       Impact factor: 9.867

View more
  1 in total

1.  MiR-125b-5p/TPD52 Axis Affects Proliferation, Migration and Invasion of Breast Cancer Cells.

Authors:  Jun Fang; Yuezhen Wang; Feiying Gu
Journal:  Mol Biotechnol       Date:  2022-03-23       Impact factor: 2.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.